{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Raphael A"],"pubmed_abstract":["<h4>Background</h4>The use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable.<h4>Methods</h4>We prospectively assessed the impact of CGP on the decision-making process in ALK-rearranged aNSCLC patients following progression on 2<sup>nd</sup>/3<sup>rd</sup>-generation ALK TKIs. Physician's choice of the most recommended next-line systemic treatment (NLST) was captured before and after receival of CGP results; the percentage of cases in which the NLST recommendation has changed was assessed along with the CGP turnaround time (TAT). Patients were divided into groups: patients in whom the NLST was initiated after (group 1) and before (group 2) receival of the CGP results. Time-to-treatment discontinuation (TTD) and overall survival (OS) with N"],"journal":["Frontiers in oncology"],"pagination":["874712"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9137396"],"repository":["biostudies-literature"],"pubmed_title":["The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2<sup>nd</sup>/3<sup>rd</sup>-Generation ALK Tyrosine Kinase Inhibitors (TKIs)."],"pmcid":["PMC9137396"],"pubmed_authors":["Peled N","Dudnik J","Zer A","Cohen AY","Dudnik E","Moskovitz M","Kian W","Bar J","Shochat T","Agbarya A","Raphael A","Oedegaard C","Grynberg S","Holtzman L","Urban D","Onn A","Rabinovich NM"],"additional_accession":[]},"is_claimable":false,"name":"The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2<sup>nd</sup>/3<sup>rd</sup>-Generation ALK Tyrosine Kinase Inhibitors (TKIs).","description":"<h4>Background</h4>The use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable.<h4>Methods</h4>We prospectively assessed the impact of CGP on the decision-making process in ALK-rearranged aNSCLC patients following progression on 2<sup>nd</sup>/3<sup>rd</sup>-generation ALK TKIs. Physician's choice of the most recommended next-line systemic treatment (NLST) was captured before and after receival of CGP results; the percentage of cases in which the NLST recommendation has changed was assessed along with the CGP turnaround time (TAT). Patients were divided into groups: patients in whom the NLST was initiated after (group 1) and before (group 2) receival of the CGP results. Time-to-treatment discontinuation (TTD) and overall survival (OS) with N","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-05-29T14:36:28.506Z","creation":"2025-02-19T02:16:19.474Z"},"accession":"S-EPMC9137396","cross_references":{"pubmed":["35646707"],"doi":["10.3389/fonc.2022.874712"]}}